Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Chief Scientific Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 986,117 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 1,673 · Balance 986,117 F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 23:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,673 | $19.66 | $32,885.16 |
DisclosureSEC source: 0001684532-26-000013 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986,117 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 22:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 939 | $19.91 | $18,691.08 |
DisclosureSEC source: 0001684532-26-000009 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 987,790 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 26, 2026 Filed Jul 28, 2026 20:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,645 | $19.67 | $32,357.15 |
DisclosureSEC source: 0001193125-26-321085 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 988,729 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 21:29 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,688 | $17.89 | $30,190.72 |
DisclosureSEC source: 0001684532-26-000005 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990,374 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2026 Filed May 28, 2026 21:19 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 945 | $17.60 | $16,632.00 |
DisclosureSEC source: 0001684532-26-000003 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 992,062 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 26, 2026 Filed Apr 28, 2026 20:52 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,645 | $16.31 | $26,829.95 |
DisclosureSEC source: 0001193125-26-187451 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993,007 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 01:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,410 | $15.33 | $98,265.30 |
DisclosureSEC source: 0001684532-26-000001 · ownership.xml · nonDerivative · entry 3 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,652 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 01:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,018 | $15.33 | $15,605.94 |
DisclosureSEC source: 0001684532-26-000001 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,001,062 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 897 | $24.76 | $22,209.72 |
DisclosureSEC source: 0001684532-26-000001 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,002,080 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 26,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 8 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,002,977 F8 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,149 | $23.09 | $188,160.41 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 7 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976,316 F7 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,661 | $23.09 | $107,622.49 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 6 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 984,465 F6 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,489 | $23.09 | $57,471.01 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 5 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 989,126 F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 22,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 4 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 991,615 F4 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 12,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 3 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 968,809 F3 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 956,047 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 403 | $23.01 | $9,273.03 |
DisclosureSEC source: 0001193125-26-072639 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951,156 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 22:02 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,331 | $27.53 | $36,642.43 |
DisclosureSEC source: 0001193125-26-027405 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951,559 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,075 | $28.33 | $30,456.69 |
DisclosureSEC source: 0001193125-25-306920 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 952,890 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $28.27 to $28.38, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 02:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 943 | $29.57 | $27,884.04 |
DisclosureSEC source: 0001193125-25-304293 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 953,965 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $29.45 to $29.67, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 535 | $30.47 | $16,303.06 |
DisclosureSEC source: 0001193125-25-297321 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 954,908 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 26, 2025 Filed Oct 28, 2025 21:20 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,642 | $23.74 | $38,981.08 |
DisclosureSEC source: 0001193125-25-253873 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 955,443 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:33 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,063 | $22.03 | $23,414.38 |
DisclosureSEC source: 0001684532-25-000014 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 957,085 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 22:55 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 943 | $21.48 | $20,260.07 |
DisclosureSEC source: 0001684532-25-000010 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958,148 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 548 | $21.50 | $11,782.88 |
DisclosureSEC source: 0001684532-25-000005 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 959,091 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 26, 2025 Filed Jul 29, 2025 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,642 | $18.37 | $30,163.54 |
DisclosureSEC source: 0000950170-25-099791 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 959,639 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 754 | $20.29 | $15,299.26 |
DisclosureSEC source: 0000950170-25-081048 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961,281 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $20.01 to $20.70, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 656 | $20.52 | $13,459.09 |
DisclosureSEC source: 0000950170-25-078346 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 962,035 F3 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F4 · price: The shares were sold in multiple transactions at prices ranging from $20.445 to $20.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 383 | $20.58 | $7,880.34 |
DisclosureSEC source: 0000950170-25-078346 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 962,691 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $20.41 to $20.79, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:53 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 79 | $17.35 | $1,370.65 |
DisclosureSEC source: 0000950170-25-062886 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 963,074 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,157 | $18.88 | $21,844.16 |
DisclosureSEC source: 0000950170-25-060278 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 963,153 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 985 | $15.45 | $15,218.25 |
DisclosureSEC source: 0000950170-25-032772 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,310 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,523 | $16.24 | $40,973.52 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 8 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 965,295 F8 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 37,790 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 7 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 967,818 F7 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2025, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,639 | $16.29 | $75,569.31 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 6 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930,028 F6 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,636 | $16.29 | $26,650.44 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 5 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 934,667 F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,211 | $16.29 | $19,727.19 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 4 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,303 F4 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 11,926 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 3 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 937,514 F3 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,588 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029435 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 921,017 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 22:25 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 417 | $16.46 | $6,863.82 |
DisclosureSEC source: 0000950170-25-026884 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 917,633 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 90 | $17.00 | $1,530.00 |
DisclosureSEC source: 0000950170-25-012439 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 918,050 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| January 26, 2025 Filed Jan 28, 2025 21:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,329 | $17.21 | $22,872.09 |
DisclosureSEC source: 0000950170-25-009841 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 918,140 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:40 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,373 | $19.50 | $26,773.36 |
DisclosureSEC source: 0000950170-24-133308 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919,469 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $19.46 to $19.58, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 22:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 497 | $18.26 | $9,074.87 |
DisclosureSEC source: 0000950170-24-131595 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 920,842 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $18.12 to $18.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 20:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 79 | $20.27 | $1,601.33 |
DisclosureSEC source: 0000950170-24-120110 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 921,339 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| October 26, 2024 Filed Oct 29, 2024 20:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,639 | $19.42 | $31,829.38 |
DisclosureSEC source: 0000950170-24-118288 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 921,418 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:20 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,503 | $21.96 | $33,007.38 |
DisclosureSEC source: 0000950170-24-104016 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,057 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.815 to $22.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:34 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 563 | $22.83 | $12,854.98 |
DisclosureSEC source: 0000950170-24-101991 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 924,560 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $22.72 to $22.915, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 20:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 111 | $23.95 | $2,658.45 |
DisclosureSEC source: 0000950170-24-089239 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,123 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.